Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC) - MyChesCo
BERWYN, PA — Panavance Therapeutics Inc., a clinical-stage pharmaceutical company, announced the recent publication of positive preliminary data in a manuscript titled, “The effect of GP‑2250 on cultured virus‑negative Merkel …
MyChesCo
